Over the past six months, Solventum’s stock price fell to $67.18. Shareholders have lost 6% of their capital, which is disappointing considering the S&P 500 has climbed by 2.6%. This may have investors wondering how to approach the situation.
Is there a buying opportunity in Solventum, or does it present a risk to your portfolio? See what our analysts have to say in our full research report, it’s free.
Why Do We Think Solventum Will Underperform?
Even with the cheaper entry price, we're sitting this one out for now. Here are three reasons we avoid SOLV and a stock we'd rather own.
1. Slow Organic Growth Suggests Waning Demand In Core Business
We can better understand Surgical Equipment & Consumables - Diversified companies by analyzing their organic revenue. This metric gives visibility into Solventum’s core business because it excludes one-time events such as mergers, acquisitions, and divestitures along with foreign currency fluctuations - non-fundamental factors that can manipulate the income statement.
Over the last two years, Solventum’s organic revenue averaged 2.3% year-on-year growth. This performance slightly lagged the sector and suggests it may need to improve its products, pricing, or go-to-market strategy, which can add an extra layer of complexity to its operations. 
2. EPS Trending Down
Analyzing the long-term change in earnings per share (EPS) shows whether a company's incremental sales were profitable – for example, revenue could be inflated through excessive spending on advertising and promotions.
Sadly for Solventum, its EPS declined by 31.6% annually over the last three years while its revenue was flat. This tells us the company struggled because its fixed cost base made it difficult to adjust to choppy demand.
3. Free Cash Flow Margin Dropping
Free cash flow isn't a prominently featured metric in company financials and earnings releases, but we think it's telling because it accounts for all operating and capital expenses, making it tough to manipulate. Cash is king.
As you can see below, Solventum’s margin dropped by 26.7 percentage points over the last four years. If its declines continue, it could signal increasing investment needs and capital intensity. Solventum’s free cash flow margin for the trailing 12 months was breakeven.
Final Judgment
Solventum doesn’t pass our quality test. After the recent drawdown, the stock trades at 10.1× forward P/E (or $67.18 per share). This valuation multiple is fair, but we don’t have much confidence in the company. There are better investments elsewhere. We’d recommend looking at an all-weather company that owns household favorite Taco Bell.
High-Quality Stocks for All Market Conditions
ALSO WORTH WATCHING: Top 5 Momentum Stocks. The best time to own a great stock is when the market is finally noticing it. These aren't just high-quality businesses. Something is happening with them right now. Elite fundamentals meeting near-term momentum — both boxes checked at the same time.
Find out which stocks our AI platform is flagging this week. See this week's Strong Momentum stocks — FREE. Get Our Strong Momentum Stocks for Free HERE.
Stocks that have made our list include now familiar names such as Nvidia (+1,326% between June 2020 and June 2025) as well as under-the-radar businesses like the once-small-cap company Comfort Systems (+782% five-year return). Find your next big winner with StockStory today.
